1. Home
  2. ACN vs VRTX Comparison

ACN vs VRTX Comparison

Compare ACN & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Accenture plc (Ireland)

ACN

Accenture plc (Ireland)

HOLD

Current Price

$193.71

Market Cap

116.0B

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$513.77

Market Cap

123.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACN
VRTX
Founded
1989
1989
Country
Ireland
United States
Employees
N/A
N/A
Industry
Business Services
EDP Services
Sector
Consumer Discretionary
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
116.0B
123.4B
IPO Year
2016
2006

Fundamental Metrics

Financial Performance
Metric
ACN
VRTX
Price
$193.71
$513.77
Analyst Decision
Buy
Buy
Analyst Count
21
29
Target Price
$270.81
$539.69
AVG Volume (30 Days)
4.1M
922.0K
Earning Date
03-19-2026
05-04-2026
Dividend Yield
3.62%
N/A
EPS Growth
N/A
836.54
EPS
10.27
8.33
Revenue
$69,672,977,000.00
$2,488,652,000.00
Revenue This Year
$7.44
$10.79
Revenue Next Year
$5.26
$10.47
P/E Ratio
$17.91
$61.88
Revenue Growth
N/A
46.20
52 Week Low
$118.15
$374.17
52 Week High
$291.09
$560.25

Technical Indicators

Market Signals
Indicator
ACN
VRTX
Relative Strength Index (RSI) 60.70 48.59
Support Level $187.86 $425.34
Resistance Level $198.78 $533.67
Average True Range (ATR) 4.99 9.76
MACD -1.24 -5.59
Stochastic Oscillator 79.43 24.69

Price Performance

Historical Comparison
ACN
VRTX

About ACN Accenture plc (Ireland)

Accenture is a leading IT services firm that provides consulting, system integration, and business process outsourcing to enterprises around the world. Customers of Accenture come from a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture is the world's largest professional services company by headcount, with around 800,000 employees in over 120 countries.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: